News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elk OrthoBiologics to Present at Biotech Showcase 2013


1/3/2013 8:15:10 AM

VICTORIA, Australia, Jan. 3, 2013 /PRNewswire/ -- Elk OrthoBiologics Limited, an Australian biotechnology company developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants, announced today that Andrew Bray, Ph.D., Managing Director and Chief Executive Officer, will present at Biotech Showcase 2013 being held January 7-9, 2013 in San Francisco, CA. Dr. Bray will discuss the Company's recent name change from Broadvector Limited to Elk OrthoBiologics Limited, the Company's new strategic focus, details on its lead program CTL102 using its Gene Directed Enzyme Prodrug Therapy (GDEPT) technology platform for prosthetic joint repair and its plans to commence a Phase 2a program in 2013.

Details of the presentation are as follows:


Date:


Tuesday, January 8, 2013


Time:


4:45 p.m. PT


Place:


Parc 55 Wyndham San Francisco-Union Square, Powell Room (Track B)





Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences.

About Elk OrthoBiologics Limited
Elk OrthoBiologics, formerly Broadvector Limited, is an Australian-based, public unlisted biotechnology company developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants. This unique therapy avoids the need for major surgery and general anesthesia. Elk's therapy addresses an important and growing unmet medical need.

Elk's lead program CTL102 is based upon its Gene Directed Enzyme Prodrug Therapy (GDEPT) technology platform. CTL102 recently completed a successful Phase 1 clinical study in elderly patients suffering from debilitating levels of aseptic loosening. The Company expects to commence a Phase 2a study in 2013.

www.elkortho.com

INVESTORS/MEDIA CONTACT
Jenene Thomas
Elk Orthobiologics Limited
Investor Relations and Corporate Communications
Jenene.thomas@elkortho.com
+1(908) 938-1475

SOURCE Elk OrthoBiologics Limited


Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES